Skip to main content
 

February 2020

Top
  • FDA’s Actions in Response to 2019 Novel Coronavirus at Home and Abroad

    Thursday, February 20, 2020

    The FDA plays an essential role in overseeing our Nation’s medical products as part of our vital mission to protect and promote public health, including during public health emergencies. The FDA is an active partner in the Novel Coronavirus (COVID-19) response, working closely with our government and public health partners across the U.S. Department of Health and Human Services, as well as with our international counterparts. Our work is multifaceted, focusing on actively facilitating efforts to diagnose, treat and prevent the disease; surveilling the medical product supply chain for potential shortages or disruptions and helping to mitigate such impacts, as necessary; and leveraging the full breadth of our public health tools as we oversee the safety and quality of FDA-regulated products for American patients and consumers.

    Read More
  • Medtronic Recalls MiniMed Insulin Pumps for Incorrect Insulin Dosing

    Thursday, February 13, 2020

    The FDA has identified this as a Class I recall, the most serious type of recall.  Use of these devices may cause serious injuries or death.

    Read More
  • CMS Prepares Nation’s Healthcare Facilities for Coronavirus Threat

    Monday, February 10, 2020

    Agency reinforces infection control responsibilities and guidelines for testing to detect coronavirus.

    Read More
  • Novel Coronavirus (2019-nCoV)

    Thursday, February 6, 2020

    FDA is working with U.S. Government partners, including the U.S. Centers for Disease Control and Prevention (CDC), and international partners to closely monitor an outbreak caused by a novel (new) coronavirus first identified in Wuhan City, Hubei Province, China.

    Read More